The methylation status of the MGMT (O6-methylguanine-DNA methyltransferase) promoter is a crucial biomarker in gliomas, particularly in predicting the response to temozolomide (TMZ) chemotherapy. This evidence concerns the gene MGMT and central nervous system cancer.